Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas

Updated on: January 04,2024 9

Trial demonstrates acute lymphoblastic leukemia treatment advance

by Diane Dragaud, ECOG-ACRIN Cancer Research GroupCredit:LBA-1 Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblas

Updated on:January 04,2024 9

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainA Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment wi

Updated on: January 04,2024 9

Trial demonstrates one-year progression-free survival in 94% of patients with stage 3 or 4 classic Hodgkin lymphoma

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainA Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment wi

Updated on:January 04,2024 9

Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

byDana-Farber Cancer InstituteNew research shows that genetics account for only five to 10 per cent of risk for most human diseases, and that gene testing is a poor predictor of whether someone

Updated on: January 04,2024 9

Three-drug combination therapy effective in patients with high-risk chronic lymphocytic leukemia, trial shows

byDana-Farber Cancer InstituteNew research shows that genetics account for only five to 10 per cent of risk for most human diseases, and that gene testing is a poor predictor of whether someone

Updated on:January 04,2024 9

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva

Updated on: January 04,2024 8

Trial results show PARP inhibitor benefit in 'BRCA-like' breast cancer

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainResults from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free surviva

Updated on:January 04,2024 8

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs

Updated on: January 04,2024 9

Results of trial will help guide treatment of malignant bowel obstruction in patients with advanced cancer

by SWOG Cancer Research NetworkCredit: CC0 Public DomainFindings from the first-ever prospective trial including a randomized pathway comparing surgery to non-surgical treatment of malignant bowel obs

Updated on:January 04,2024 9

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,

Updated on: January 04,2024 8

Trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity,

Updated on:January 04,2024 8

Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show

Updated on: January 04,2024 10

Trial finds adding immune modulator to targeted therapy does not improve survival in difficult-to-treat thyroid cancer

byUniversity of Chicago Medical CenterCredit: Pixabay/CC0 Public DomainResults of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show

Updated on:January 04,2024 10

Chemotherapy before surgery cuts risk of colon cancer returning, trial finds

byCancer Research UKCredit: CC0 Public DomainGiving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to the results of a Cancer Research UK

Updated on: January 04,2024 6

Chemotherapy before surgery cuts risk of colon cancer returning, trial finds

byCancer Research UKCredit: CC0 Public DomainGiving colon cancer patients chemotherapy before surgery cuts their risk of the disease coming back, according to the results of a Cancer Research UK

Updated on:January 04,2024 6

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was

Updated on: January 04,2024 9

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was

Updated on:January 04,2024 9

World-first use of base-edited CAR T cells to treat resistant leukemia

byUniversity College LondonCredit: Unsplash/CC0 Public DomainA patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a

Updated on: January 04,2024 9

World-first use of base-edited CAR T cells to treat resistant leukemia

byUniversity College LondonCredit: Unsplash/CC0 Public DomainA patient with relapsed T cell leukaemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a

Updated on:January 04,2024 9

World-first clinical trial with 'man's best friend' could unlock treatment breakthrough for kids with cancer

by Telethon Kids InstituteThree-year-old Bull Terrier, Maggie, is about to undergo surgery using the immunotherapy gel to treat her sarcoma. It is hoped the world-first clinical trial in dogs will be

Updated on: January 04,2024 9

World-first clinical trial with 'man's best friend' could unlock treatment breakthrough for kids with cancer

by Telethon Kids InstituteThree-year-old Bull Terrier, Maggie, is about to undergo surgery using the immunotherapy gel to treat her sarcoma. It is hoped the world-first clinical trial in dogs will be

Updated on:January 04,2024 9

Normalizing tumor blood vessels may improve immunotherapy against brain cancer

by Noah Brown,Massachusetts General HospitalAnti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to ev

Updated on: January 04,2024 9

Normalizing tumor blood vessels may improve immunotherapy against brain cancer

by Noah Brown,Massachusetts General HospitalAnti-VEGF treatment improves the efficacy of EGFRvIII-CAR-T cells in murine GBM tumor models. (A) Schematic representation of experimental setup to ev

Updated on:January 04,2024 9